Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 6, 2008, Pages 1520-1526

  Hellstrom, Ingegerd ^a   Friedman, Eitan ^b,c   Verch, Thorsten ^d   Yang, Yi ^a   Korach, Jacob ^c   Jaffar, Jade ^a   Swisher, Elizabeth ^e   Zhang, Boxin ^e   Ben Baruch, Gilad ^c   Tan, Marcus C B ^f   Goedegebuure, Peter ^f   Hellstrom, Karl Erik ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d FUJIREBIO INC   (Japan)

^e UNIVERSITY OF WASHINGTON   (United States)

^f WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MESOTHELIN; MESOTHELIN ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GYNECOLOGIC DISEASE; HUMAN; HUMAN CELL; OUTCOMES RESEARCH; OVARY CANCER; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 53349175801     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0039     Document Type: Article

References (27)

1. Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 1999;96:11531-6.
2. Robinson BWS, Creaney J, Lake RL, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-6.
3. McIntosh MW, Drescher C, Karlan B, et al. Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004;95:9-15.
4. Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005;99:267-77.
5. Hellstrom I, Raycraft J, Kanan S, et al. Mesothelin-variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006;15:1014-20.
6. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006;12:447-53.
7. Hassan R, Bera TK, Pastan I. Mesothelin: a new target for immunothearpy. Clin Cancer Res 2004;10:3937-42.
8. Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004;279:9190-8.
9. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med 1998;187:1163-7.
10. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997;15:3363-7.
11. Goodell V, Disis ML. Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity. J Immunol Methods 2005;299:129-38.
12. Cramer DW, Titus-Ernstoff L, McKolanis JR, et al. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to riskfor ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1125-31.
13. Luborsky J. Ovarian autoimmune disease and ovarian autoantibodies. J Womens Health Gend Based Med 2002;11:585-99.
14. Luborsky JL, Barua A, Shatavi SV, Kebede T, Abramowicz J, Rotmensch J. Anti-tumor antibodies in ovarian cancer. Am J Reprod Immunol 2005;54:55-62.
15. Ho MH, Hassan R, Zhang J, et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005;11:3814-20.
16. Zhang P, Ren J, Shen Z. A new quantitative method for circulating DNA level in human serum by capillary zone electrophoresis with laser-induced fluorescence detection. Electrophoresis 2004;25:1823-8.
17. Beyer HL, Geschwindt RD, Glover CL, et al. MESOMARK (TM): a potential test for malignant pleural mesothelioma. Clin Chem 2007;534:666-72.
18. Eng K, McCormick AL, Yates JI. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 1994;5:976-89.
19. Chittum HS, Lane WS, Carlson BA, et al. Rabbit betaglobin is extended beyond its UGA stop codon by multiple suppressions and translational reading gaps. Biochemistry 1998;37:10866-70.
20. Chang K, Pai LH, Batra JK, Pastan I, Willingham MC. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res 1992;52:181-6.
21. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93:136-40.
22. + T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004;200:297-306.
23. Hellstrom KE, Hellstrom I. Tumor antigens. Encyclopedia of cancer. Bertino J, editor. 2nd ed. Academic Press: 2002; p. 459-66.
24. Gershon RK, Mokyr MB, Mitchell MS. Activation of suppressor T cells by tumour cells and specific antibody. Nature 1974;250:594-6.
25. deVisser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005;7:411-3.
26. Prehn RT. Do tumors grow because of the immune response of the host. Immunol Rev 1976;38:34-2.
27. Luborsky J, Barua A, Bitteman P, Rotmensch J, Hales D, Bahr J. Antitumor and anti-ovarian antibodies associated with ovarian cancer in humans and hens. 1st International Conference on Ovarian Cancer; Crete, Greece; 2006.